Related Experiment Video
Updated: Jun 12, 2026

Sub-acute Cerebral Microhemorrhages Induced by Lipopolysaccharide Injection in Rats
Published on: October 17, 2018
Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based,
S M Gregoire1, H R Jäger, T A Yousry
1Stroke Research Group, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.
Background:
Intracerebral haemorrhage (ICH) is an uncommon but devastating complication of regular antiplatelet use: identifying high-risk patients before treatment could potentially reduce this hazard. Brain microbleeds on gradient-recalled echo (GRE) T2*-weighted MRI are considered a biomarker for bleeding-prone small-vessel diseases. The authors hypothesised that microbleeds are a risk factor for antiplatelet-related ICH, and investigated this in a hospital-based matched case-control study.
Methods:
Cases of spontaneous ICH were ascertained, using overlapping methods, from a prospective database of 1017 consecutive unselected patients referred to our stroke unit and associated clinics. For each case of antiplatelet-related ICH, two controls matched for age, sex and hypertension without history of ICH on antiplatelet therapy were selected. Microbleeds were identified by a trained observer blinded to clinical details.
Results:
Microbleeds were more frequent in antiplatelet users with ICH than in matched antiplatelet users without ICH (13/16 (81%) vs 6/32 (19%), p=0.004) and patients with non-antiplatelet-related ICH (13/16 (81%) vs 15/33 (45%), p=0.03). The frequency of lobar microbleeds was 11/16 (69%) in antiplatelet-related ICH versus 11/33 (33%) in non antiplatelet-related ICH (p=0.032). Microbleeds were more numerous in antiplatelet users with ICH compared with controls (p=0.016). The number of microbleeds was associated with the risk of antiplatelet-related ICH (adjusted OR 1.33 per additional microbleed, 95% CI 1.06 to 1.66, p=0.013).
Conclusions:
Brain microbleeds are associated with antiplatelet-related ICH. In patients with a large number of lobar microbleeds, the risk of ICH could outweigh the benefits of antiplatelet therapy. Larger prospective studies to investigate the prognostic significance of microbleeds in regular antiplatelet users are warranted.
Insights
Brain microbleeds detected by MRI are linked to a higher risk of intracerebral haemorrhage (ICH) in patients taking antiplatelet medication. Identifying these microbleeds may help predict ICH risk before starting antiplatelet therapy.
Area of Science:
- Neurology
- Radiology
- Cardiovascular Medicine
Background:
- Intracerebral haemorrhage (ICH) is a severe complication of antiplatelet therapy.
- Brain microbleeds on MRI are potential biomarkers for small-vessel disease and bleeding risk.
- Identifying patients at high risk for ICH is crucial to mitigate treatment hazards.
Purpose of the Study:
- To investigate whether brain microbleeds are a risk factor for antiplatelet-related ICH.
- To assess the association between microbleeds and the occurrence of ICH in patients using antiplatelet drugs.
Main Methods:
- A hospital-based, matched case-control study was conducted.
- Cases of spontaneous ICH were identified from a prospective database.
- Two controls per case were matched for age, sex, and hypertension, without prior ICH or antiplatelet use; microbleeds were assessed by a blinded observer.
Main Results:
- Microbleeds were significantly more frequent in patients with antiplatelet-related ICH (81%) compared to controls (19%) and non-antiplatelet-related ICH (45%).
- The number of microbleeds was associated with an increased risk of antiplatelet-related ICH (adjusted OR 1.33 per additional microbleed).
- Lobar microbleeds were also more common in the antiplatelet-related ICH group.
Conclusions:
- Brain microbleeds are significantly associated with an increased risk of intracerebral haemorrhage in patients using antiplatelet therapy.
- A high number of lobar microbleeds may indicate that the risks of antiplatelet therapy outweigh the benefits.
- Further prospective studies are recommended to confirm the prognostic value of microbleeds in regular antiplatelet users.
Related Concept Videos
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology

